Histo-clinical variation in multiple sclerosis: Heterogeneous proteolytic immunogenic processing

Fred C Westall1

  • 1Institute for Disease Research, P.O. Box 890193, Temecula, CA 92589-0193, USA. fcwestallidr@adelphia.net

Medical Hypotheses
|October 21, 2005
PubMed

Insights

Multiple sclerosis (MS) variation may stem from how proteases process myelin proteins. This hypothesis explains the unpredictable relapses and varied symptoms seen in MS patients.

Area of Science:

  • Neuroimmunology
  • Proteomics

Background:

  • Multiple sclerosis (MS) exhibits significant histo-clinical variation, including unpredictable relapses and diverse initial symptoms.
  • Current theories, suggesting MS is a collection of diseases, fail to adequately explain this wide spectrum of clinical presentations.
  • MS appears as a continuum of disease courses rather than distinct, well-defined disease types.

Purpose of the Study:

  • To propose a novel hypothesis explaining the histo-clinical variation in multiple sclerosis.
  • To investigate the role of proteolytic processing of myelin components in MS pathogenesis.
  • To offer a framework for understanding the unpredictable nature of MS progression.

Main Methods:

  • The study presents a hypothesis based on the variable proteolytic processing of potential myelin immunogens.
  • It discusses the role of intracellular and extracellular proteases in the central nervous system (CNS).
  • The hypothesis considers the varying concentrations and locations of proteases within the CNS.

Main Results:

  • Variable proteolytic processing of myelin proteins can lead to the presentation of different immunogenic peptides to the immune system.
  • Differences in protease location, concentration, and control can result in the presentation of varying numbers and types of immunogens at different times and locations.
  • This dynamic presentation of immunogens by proteases offers a potential explanation for the variable initial and subsequent symptoms observed in MS.

Conclusions:

  • Histo-clinical variation in MS is hypothesized to be driven by variable proteolytic processing of myelin-derived immunogens.
  • Protease activity within the CNS dictates the presentation of immunogenic peptides, influencing disease presentation and progression.
  • This hypothesis provides a unified explanation for the diverse clinical spectrum of multiple sclerosis.